|
|
Cat. No |
Model |
Description |
Unit |
Price (VATº°µµ) |
³³±â |
Àç°í |
DataSheet |
ÁÖ¹®/°ßÀû |
LCA-24-366985 |
AP06511PU-N |
ABCC7 / CFTR//Human, Mouse/Rabbit |
1/EA |
|
|
|
|
¹®ÀÇ |
|
|
|
|
|
|
Subject
|
ABCC7 / CFTR |
Description
|
/ Human, Mouse/Rabbit |
Clonality
|
Mono |
Company
|
Acris Antibodies GmbH |
Application
|
Enzyme Immunoassay, Paraffin Sections |
Conjugation
|
|
Immunogen
|
|
Contents
|
Description: Manufacturer | Acris Antibodies GmbH | Quantity | 100 ug | Reactivity | Human, Mouse | Presentation | Aff - Purified | Applications | Enzyme Immunoassay, Paraffin Sections | Host | Rabbit | PDF datasheet | view | Shipping to | Worldwide | Synonyms | Cystic fibrosis transmembrane conductance regulator | Swiss Prot Num | P13569 | Product Type | Antibodies | Storage | Store the antibody undiluted at 2-8°C. DO NOT FREEZE! Shelf life: one year from despatch. | |
Format | State: Liquid purified Ig | ? | Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) | ? | Buffer System: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.2. | |
Specificity | CFTR (E733) antibody detects endogenous levels of CFTR protein. | Application | ELISA: 1:1000~1:5000. IHC: 1:50~1:200. | Background | CFTR, for cystic fibrosis transmembrane conductance regulator, is a cyclic adenosine monophosphate (cAMP)-regulated chloride channel protein. CFTR belongs to the MDR subfamily within the ATP-binding transport protein family. It has two transmembrane domains (TMDs), two nucleotide binding domains (NBDs) and one regulatory domain. Mutations of CFTR are associated with cystic fibrosis (CF), a disease characterized by chronic bronchopulmonary disease, elevated sweat electrolytes and insufficient pancreatic function. CFTR mutations can also result in congenital bilateral absence of vas deferens (CBAVD), a form of male sterility that a majority of male CF patients exhibit. | Concentration | 1,0 mg/ml | |
|
|
|
|